An observational study in Idiopathic Pulmonary Fibrosis, sponsored by 23andMe, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-09.
Sponsored by 23andMe, Inc. · Observational
The long term goal of this study is to increase genetic understanding of IPF to enable the development of an effective drug for IPF that can improve the lives of those living with the condition.
This study will recruit 1,000 people who have been diagnosed with IPF or Hermansky-Pudlak syndrome (HPS). Eligible participants who consent to participate in 23andMe Research and the IPF Research Study will receive a 23andMe Health + Ancestry kit at no cost. Participants will provide a saliva sample and take a baseline survey online answering questions about their disease diagnosis, testing, treatment, and symptoms. Participants will also be asked to take the same survey 3, 6, and 9 months after completing the baseline survey. The data collected from this study will be incorporated into the 23andMe Database and used to better understand the underlying genetic and environmental factors that contribute to IPF.
680 studies on the registry are indexed under Pulmonary Fibrosis; 119 are open to participants now.
This study's enrollment of 690 is above the median of 130 across 229 observational studies indexed under Pulmonary Fibrosis.
Browse Pulmonary Fibrosis studies →23andMe, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will only include participants who meet the eligibility criteria as described above. Participants in the study will be diagnosed with IPF or HPS.
Exclusion Criteria:
Participants diagnosed with idiopathic pulmonary fibrosis
Other: No intervention
No intervention
IPF Symptom Progression Baseline
Survey asking about disease diagnosis, testing, treatments, and symptom progression
Time frame: Baseline
IPF Symptom Progression 3 month follow-up
IPF Symptom Progression 3 month follow-up
Time frame: 3 months post baseline
IPF Symptom Progression 6 month follow-up
Survey asking about disease diagnosis, testing, treatments, and symptom progression
Time frame: 6 months post baseline
IPF Symptom Progression 9 month follow-up
Survey asking about disease diagnosis, testing, treatments, and symptom progression
Time frame: 9 months post baseline
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
23andMe, Inc.